Kuca-Warnawin Ewa, Kurowska Weronika, Plebańczyk Magdalena, Wajda Anna, Kornatka Anna, Burakowski Tomasz, Janicka Iwona, Syrówka Piotr, Skalska Urszula
Department of Pathophysiology and Immunology, National Institute of Geriatrics, Rheumatology and Rehabilitation, 02-637 Warsaw, Poland.
Department of Molecular Biology, National Institute of Geriatrics, Rheumatology and Rehabilitation, 02-637 Warsaw, Poland.
Pharmaceutics. 2023 Mar 20;15(3):1003. doi: 10.3390/pharmaceutics15031003.
Rheumatoid arthritis (RA) and osteoarthritis (OA) are destructive joint diseases, the development of which are associated with the expansion of pathogenic T lymphocytes. Mesenchymal stem cells may be an attractive therapeutic option for patients with RA or OA due to the regenerative and immunomodulatory abilities of these cells. The infrapatellar fat pad (IFP) is a rich and easily available source of mesenchymal stem cells (adipose-derived stem cells, ASCs). However, the phenotypic, potential and immunomodulatory properties of ASCs have not been fully characterised. We aimed to evaluate the phenotype, regenerative potential and effects of IFP-derived ASCs from RA and OA patients on CD4+ T cell proliferation. The MSC phenotype was assessed using flow cytometry. The multipotency of MSCs was evaluated on the basis of their ability to differentiate into adipocytes, chondrocytes and osteoblasts. The immunomodulatory activities of MSCs were examined in co-cultures with sorted CD4+ T cells or peripheral blood mononuclear cells. The concentrations of soluble factors involved in ASC-dependent immunomodulatory activities were assessed in co-culture supernatants using ELISA. We found that ASCs with PPIs from RA and OA patients maintain the ability to differentiate into adipocytes, chondrocytes and osteoblasts. ASCs from RA and OA patients also showed a similar phenotype and comparable abilities to inhibit CD4+ T cell proliferation, which was dependent on the induction of soluble factors The results of our study constitute the basis for further research on the therapeutic potential of ASCs in the treatment of patients with RA and OA.
类风湿关节炎(RA)和骨关节炎(OA)是破坏性关节疾病,其发展与致病性T淋巴细胞的扩增有关。由于间充质干细胞具有再生和免疫调节能力,它们可能是RA或OA患者有吸引力的治疗选择。髌下脂肪垫(IFP)是间充质干细胞(脂肪来源干细胞,ASCs)丰富且易于获取的来源。然而,ASCs的表型、潜能和免疫调节特性尚未完全明确。我们旨在评估来自RA和OA患者的IFP来源ASCs的表型、再生潜能以及对CD4+T细胞增殖的影响。使用流式细胞术评估MSC表型。基于MSCs分化为脂肪细胞、软骨细胞和成骨细胞的能力来评估其多能性。在与分选的CD4+T细胞或外周血单个核细胞共培养中检测MSCs的免疫调节活性。使用酶联免疫吸附测定法(ELISA)评估共培养上清液中参与ASC依赖性免疫调节活性的可溶性因子浓度。我们发现来自RA和OA患者的带有质子泵抑制剂的ASCs保持分化为脂肪细胞、软骨细胞和成骨细胞的能力。来自RA和OA患者的ASCs也表现出相似的表型和相当的抑制CD4+T细胞增殖的能力,这依赖于可溶性因子的诱导。我们的研究结果构成了进一步研究ASCs在治疗RA和OA患者中的治疗潜能的基础。